Benign Prostatic Hyperplasia

“If you haven't used HYDROS before, or if you're concerned about doing bigger glands or tackling more difficult cases, I think we've shown in our first 35-40,000 cases that Aquablation, the therapy, is a valid therapy,” says Lewis S. Kriteman, MD, FACS.

"The evolution is continuing, now with a decade of human use of Aquablation, we can now take this to a same-day procedure––discharge the same calendar day," says Kevin C. Zorn, MD, FRCSC, FACS.

"I think it's going to help younger or less experienced urologists get more proficient at this procedure faster. That's where the AI is going to come into play," says Lewis S. Kriteman, MD, FACS.

“The technology is there, the experience is there now, and it's bringing it all together to lead to better outcomes [and a] shorter hospital stay,” says Kevin C. Zorn, MD, FRCSC, FACS.

“I think particularly as we've had the technology for longer and we've used it more and become more comfortable with it, there's really nobody, necessarily, that can't be considered for it,” says Aaron M. Bernie, MD, MPH.

"The first part is how much [are patients] bothered by the symptoms?" says Akhil Das, MD, FACS.

"I'd be curious to see a validated study on whether prostate sizes have increased over time. I suspect the answer will be yes," says Joseph Song, MD.

“We've been developing different techniques in HoLEP, but there is a steep learning curve,” says Akhil Das, MD.

"From a learning curve standpoint, there's not much to learn. It tends to be fairly quick in terms of your ability to do the procedure," says Matthew E. Sterling, MD.

“Our results demonstrated that treatment with [the] Optilume BPH procedure resulted in significant symptom relief while still preserving erectile and ejaculatory function,” said Olivia Copelan, MD.

"The results showed the contemporary Aquablation procedural safety in Japanese men is exceptional in a broad range of prostate sizes along with significant symptom reduction," says Nobuyuki Hinata, MD.

"Within this paper, we discussed the importance of conservative management and lifestyle modifications as initial steps in managing BPH," says Eiftu S. Haile, MD.

In this final iteration of a 3-part series, Shawn H. Marhamati, MD, MS, shares initial insights into benefits of Aquablation in an ASC environment.

"Alpha-blockers are often, for patients, the first line of treatment because they help quickly relax the smooth muscles in the bladder and the prostate," says Eiftu S. Haile, MD.

"For those who do enucleations, I think I would encourage people to highly consider adopting an apical release technique if they haven't," says Daniel J. Heidenberg, MD.

In this second iteration of a 3-part series, Shawn H. Marhamati, MD, MS, highlights the experiences and data that supported the trial of Aquablation in an ASC setting.

In this first video of a 3-part series, Shawn H. Marhamati, MD, MS discusses a pilot trial of Aquablation in an ASC setting and highlights the benefits of the therapy.

iTind is a temporary nitinol device used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia.

"I don't think anybody, at least in our Mayo Clinic practices, is ever doing anything other than apical release HoLEPs these days," says Daniel J. Heidenberg, MD.

"But I think that this really showed us that the outcomes were substantially better than I think any of us were thinking," says Daniel J. Heidenberg, MD.

Dr. Heidenberg discusses the recent Urology paper, “The Impact of Standard vs Early Apical Release HoLEP Technique on Postoperative Incontinence and Quality of Life.”

“The UroLift 2 ATC is designed to deliver the same proven effectiveness of the UroLift System, with significant enhancements on a unified UroLift 2 platform,” says Brian Wilkins.

"We really aimed to affect 3 different contraindications and instead achieved retirement of the entire policy, which, we think, really opens up this wonderful technology to literally hundreds of thousands more patients across the country," says Arpeet Shah, MD.

“We're always so focused on the prostate. That's the million-dollar question: are we getting to bladders too late?” says Kevin C. Zorn, MD, FRCSC, FACS.

“It's exciting to see that we now have another offering to men with enlarged prostates that has good outcomes and good durability up to 5 years [based on] the trials,” Kevin C. Zorn, MD, FRCSC, FACS.

"The ProVee System has the potential to be a first-line interventional therapy for BPH that can be safely and reliably performed in the office setting," says Steven A. Kaplan, MD.

"I think it's important that they go visit someone that does them. Go to the operating room, see it in person," says Matthew E. Sterling, MD.

“These are the technologies that we'll see to empower patients and get more information, so that when we see the patient, it's one less thing we as a physician have to gather during that consultation, making the consultation more efficient,” says Kevin C. Zorn, MD, FRCSC, FACS.